ArticleMethods in molecular biology (Clifton, N.J.)2026
Canine Model of Duchenne Muscular Dystrophy.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dystrophin-deficient canines are the best-characterized large animal model for Duchenne muscular dystrophy (DMD). Unlike dystrophin-null mice, affected dogs display many phenotypical features of human patients. Furthermore, dogs' body size and body weight are much closer to humans than those of mice's. These features make affected canines an excellent model system for studying pathogenic mechanisms of the disease and for testing novel experimental therapeutics. The golden retriever muscular dystrophy (GRMD) dog is the first canine DMD model with a confirmed null mutation in the DMD gene. Since then, dystrophin-deficient dogs have been identified in many different breeds. Research colonies have been established worldwide. Here, we describe our experience in generating and maintaining affected dogs. Adeno-associated virus (AAV) vectors have been used to restore dystrophin expression by gene replacement or gene repair therapies. We provide protocols for intramuscular AAV injection in adult canines and systemic delivery of AAV to neonatal and young adult canines. We also include a muscle biopsy protocol for periodic monitoring of gene transfer before the terminal study.
Indexed as
Identifiers
41028318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.